A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

Clinical trial NCT05661916 · COMPLETED

Trial details

NCT number: NCT05661916
Sponsor: Alnylam Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Transthyretin-Mediated Amyloidosis

Start date: 2023-01-16
Primary completion: 2025-09-30
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.